BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 31, 2020
View Archived Issues
Activity against AML seen in vitro and in vivo with LSD1 inhibitor CPI-482
Read More
Phase II results reported for AXL inhibitor bemcentinib in patients failing hypomethylating agents
Read More
Sulanda approved in China for non-pancreatic NETs
Read More
Saroglitazar magnesium approved in India for NAFLD
Read More
Altimmune initiates phase II trial of HepTcell for chronic hepatitis B
Read More
Codiak reports initial phase I data on exoIL-12 for CTCL
Read More
Arcturus selects ARCT-032 as development candidate for cystic fibrosis
Read More
FDA clears LyGenesis' IND for phase IIa study of cell therapy for end-stage liver disease
Read More
Ascendis files IND for TransCon TLR7/8 agonist
Read More
Lanzhou University synthesizes siRNAs targeting OLFML2A
Read More
New phase I/II study explores use of TY-101 for solid tumors and lymphomas
Read More
New AXL/Mer/c-Met/VEGFR-2 inhibitors discovered at Exelixis
Read More
Mirati Therapeutics describes new polycomb protein EED inhibitors
Read More
Orexin receptor antagonists patented by Hager Biosciences
Read More
University of California, Oakland presents inhibitors of activities caused by MECP2 gene mutations
Read More
Preclinical evaluation of SPR-519, a novel dual PI3K-alpha and mTOR kinase inhibitor
Read More
UBA1 gene mutations linked to novel adult-onset rheumatic disease
Read More
ImmunoPrecise Antibodies joins consortium to develop SARS-CoV-2-specific therapeutic nanomedicine
Read More
Atlas maps cleaned-up tumor microbiomes
Read More